Guiyang Xintian Pharmaceutical Co Ltd

Guiyang Xintian Pharmaceutical Co Ltd maintains a debt-to-equity ratio of 0.69, indicating a moderate level of leverage relative to its equity base. The company's liquidity is assessed as medium, with a current ratio of 0.92, suggesting that it has nearly enough current assets to cover its current liabilities, but with limited buffer. The company's operating cash flow of 32.5 million yuan supports its short-term obligations, but its capital expenditures of -39.3 million yuan indicate a net outflow from investing activities.

The company's profitability is modest, with a return on equity (ROE) of 1.45% and a return on assets (ROA) of 0.79%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, which often sees ROE and ROA in the double-digit range. The company's net income of 14.8 million yuan is relatively low compared to its revenue of 264.4 million yuan, indicating a net margin of approximately 5.6%.

Guiyang Xintian Pharmaceutical Co Ltd operates primarily in the domestic Chinese market, with no disclosed international revenue segments. The company's revenue is concentrated in a single geographic region, which increases its exposure to local economic and regulatory risks. There is no information available on specific product segments or their contribution to revenue, but the company's primary activity is in pharmaceuticals.

The company's growth trajectory is not clearly defined in the available data. There are no disclosed projections for the current or next fiscal year, and the historical revenue data does not show a clear upward or downward trend. The company's capital expenditures are negative, suggesting a reduction in investment in physical assets, which may indicate a focus on cost control or a strategic shift in capital allocation.

The company's risk profile includes a medium liquidity risk, as its current ratio is close to 1, and a low dilution risk, as there is no indication of significant share issuance or dilution potential. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations or investments without external financing.

There are no recent events or filings disclosed in the available data that would significantly impact the company's operations or financial position. The company's risk assessment does not highlight any major regulatory or operational risks beyond the standard liquidity and debt considerations.

Guiyang Xintian Pharmaceutical Co Ltd (002873.SZ) has undergone a formal classification update, with its economic sector now identified as Healthcare and its primary activity defined as Pharmaceuticals & Medical Research. This structural clarification establishes the company’s operational context within the broader healthcare industry, providing a clearer framework for sector-specific analysis. In terms of risk profile, the company’s dilution risk has been assessed as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment suggests that existing shareholders are currently protected from significant dilution pressures, a positive signal for capital preservation. Conversely, liquidity risk has been categorized as medium, highlighting potential constraints in the ease of trading the company’s shares without significantly impacting their price. This moderate liquidity profile may require investors to consider transaction costs and market depth when executing trades, distinguishing it from more liquid counterparts in the sector. These updates reflect a comprehensive review of the company’s fundamental attributes, aligning its risk and classification metrics with current market realities. The combination of low dilution risk and medium liquidity risk offers a nuanced view of the investment landscape for Guiyang Xintian Pharmaceutical, balancing capital stability with trading considerations. [doc:002873.sz-ha-financials]

Cash conversion ratio of 2.2 ranks in the top quartile, significantly exceeding the cohort median of 0.95.

Long-term debt decreased to 433 million in FY-4 from 669 million in FY0, showing a trend of deleveraging.

Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from share issuance.

Credit risk is flagged as high, indicating substantial potential for financial distress or default given current leverage levels.

Debt-to-equity ratio of 0.69 is in the bottom quartile, implying higher financial leverage risk compared to peers.

Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.09B, +12,2% YoY; Operating income +4,3% YoY.

• ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 1.09B, +12,2% YoY
• ▍Operating income +4,3% YoY
• ▍Net income +10,8% YoY
• ▍Free cash flow −109,9% YoY
• ▍Net margin 10.3%